The main indications for RRSO are risk-reducing surgery in women at risk of developing ovarian or fallopian tube cancer such as BRCA1 or BRCA2 germline mutations or hereditary (breast) and ovarian cancer (HBOC) [1]. This evidence concerns the gene BRCA1 and ovarian carcinoma.